摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-1-(3-(2-(7-氯-2-喹啉基)乙烯基苯基)-2-丙烯-1-醇 | 149968-10-5

中文名称
(E)-1-(3-(2-(7-氯-2-喹啉基)乙烯基苯基)-2-丙烯-1-醇
中文别名
——
英文名称
(E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)prop-2-en-1-ol
英文别名
1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]prop-2-en-1-ol
(E)-1-(3-(2-(7-氯-2-喹啉基)乙烯基苯基)-2-丙烯-1-醇化学式
CAS
149968-10-5
化学式
C20H16ClNO
mdl
——
分子量
321.806
InChiKey
PITUINHIXKJYJX-UXBLZVDNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    504.1±38.0 °C(Predicted)
  • 密度:
    1.263±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    33.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933499090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储条件:2-8°C,干燥且密封。

SDS

SDS:6b4aacf304b05f5ad6701089e2679a99
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • A Modular Synthesis of 2-Alkyl- and 2-Arylchromans via a Three-Step Sequence
    作者:Robert Orr、Louis-Charles Campeau、Harry Chobanian、Jamie McCabe Dunn、Barbara Pio、Christopher Plummer、Andrew Nolting、Rebecca Ruck
    DOI:10.1055/s-0036-1588075
    日期:——
    2-alkylchromans, as well as an azachroman derivative. The asymmetric version of this approach via a Noyori-catalyzed ketone reduction and subsequent cyclization is likewise highlighted. A convergent three-step method for the synthesis of 2-substituted chromans is described. These results have been accomplished via the Heck coupling of readily accessible allylic alcohols and 2-iodophenols, followed by reduction and
    摘要 描述了一种用于合成2-取代的苯并二氢吡喃的收敛三步法。这些结果通过容易获得的烯丙醇和2-碘苯酚的Heck偶联,然后还原和Mitsunobu环化完成。该方法的实用性和通用性通过一系列2-芳基,2-杂芳基和2-烷基苯并二氢吡喃以及氮杂苯并二氢吡喃衍生物的合成得到证明。同样强调了通过Noyori催化的酮还原和随后的环化反应的这种方法的不对称形式。 描述了一种用于合成2-取代的苯并二氢吡喃的收敛三步法。这些结果通过容易获得的烯丙醇和2-碘苯酚的Heck偶联,然后还原和Mitsunobu环化完成。该方法的实用性和通用性通过一系列2-芳基,2-杂芳基和2-烷基苯并二氢吡喃以及氮杂苯并二氢吡喃衍生物的合成得到证明。同样强调了通过Noyori催化的酮还原和随后的环化反应的这种方法的不对称形式。
  • [EN] A PROCESS FOR SYNTHESIZING DIOL (VIII)-AN INTERMEDIATE OF MONTELUKAST SODIUM<br/>[FR] PROCEDE POUR SYNTHETISER UN DIOL (VIII), INTERMEDIAIRE DU SODIUM DE MONTELUKAST
    申请人:MOREPEN LAB LTD
    公开号:WO2006021974A1
    公开(公告)日:2006-03-02
    A process comprises preparing benzaldehyde of formula I in a conventional manner, reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under 'Swern's conditions' to get a ketone of formula m, enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions effective to yield a β- ketoester of formula IV, benzylating the said β-ketoester so obtained in the preceding step to form the benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic conditions, alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired, asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI, treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium chloride to get the intermediate diol of formula VIII. Atemately, the said alcohol to Heck coupling with methyl-2-iodobenzoate in presence of Lewis base, acetonitrile, and palladium acetate to yield ketoester (VI), which is converted to diol (VIII) as described herein above.
    该过程包括以传统方式制备化学式I的苯甲醛,将所述苯甲醛I与格氏试剂在水溶性醚溶剂中反应,通过加入铵盐和水使醇II沉淀,随后通过任何已知方法分离沉淀的醇,然后在“Swern条件”下直接氧化以得到化学式m的酮,使所述酮在存在弱碱(如碱金属碱)的情况下烯醇化,然后在条件下与二烷基碳酸酯反应以产生化学式IV的β-酮酯,将在前一步骤中获得的β-酮酯苄化以在温和无机碱存在下形成化学式V的苯甲酸酯,随后在酸性条件下将所述苯甲酸酯脱羧为化学式VI的酮酯和其对应酸化学式VIA的混合物,将在前一步骤中存在的酸VIA烷化以获得化学式VI的酮酯,并在必要时纯化,将化学式VI的酮酯不对称还原为手性醇化学式VII,使用(-)二异萜基氯硼烷(-DIPC1)在少于4倍体积/重量的无极性溶剂和可能在存在于所述化学式VI的酮酯相对于Lewis碱的情况下,用铈卤盐和烷基镁卤化物处理所述手性醇VII,随后使用hyflow supercel和氯化铵分离标题化合物以获得化学式VIII的中间二醇。或者,将所述醇与甲基-2-碘苯酸甲酯在Lewis碱、乙腈和乙酸钯存在下进行Heck偶联反应,得到酮酯(VI),然后将其转化为所述化学式VIII的二醇,如上所述。
  • Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
    申请人:Merck Frosst Canada, Inc.
    公开号:US05270324A1
    公开(公告)日:1993-12-14
    Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    具有以下化学式的化合物 I: ##STR1## 是白三烯拮抗剂,也是白三烯生物合成的抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎症和细胞保护剂。它们还可用于治疗心绞痛、脑痉挛、肾小球肾炎、肝炎、内毒素血症、葡萄膜炎和移植排斥反应。
  • Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
    申请人:Merck Frosst Canada, Inc.
    公开号:US05565473A1
    公开(公告)日:1996-10-15
    Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    具有以下化学式I的化合物是白三烯拮抗剂和白三烯生物合成抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗心绞痛、脑痉挛、肾小球肾炎、肝炎、内毒素血症、葡萄膜炎和移植排斥反应。
  • A Novel Dual Antagonist of Thromboxane A2 and Leukotriene D4 Receptors: Synthesis and Structure-Activity Relationships of Chloroquinolylvinyl Derivatives
    作者:Yoshinori Okamoto、Masaki Yokota、Soichiro Kawazoe、Hirokazu Kubota、Hitoshi Nagaoka、Yasuhito Arakida、Makoto Takeuchi
    DOI:10.1248/cpb.54.603
    日期:——
    To discover an orally active thromboxane A(2) (TXA(2)) and leukotriene D(4) (LTD(4)) dual antagonist, we designed and synthesized chloroquinolylvinyl derivatives based on the structures of the TXA(2) antagonist daltroban and the LTD(4) antagonist montelukast. Among these derivatives, 4-[(2-(4-chlorophenylsulfonylamino)-1-3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoic acid (18d)
    要发现口服活性血栓烷A(2)(TXA(2))和白三烯D(4)(LTD(4))双重拮抗剂,我们设计和合成了基于TXA(2)拮抗剂daltroban和LTD(4)拮抗剂孟鲁司特。在这些衍生物中,4-[((2-(4-氯苯基磺酰基氨基)-1-] [3-[(E)-2-(7-氯-2-喹啉基)乙烯基]苯基}乙基)硫基]甲基}苯甲酸(18d)显示了对豚鼠回肠中U46619诱导的豚鼠血小板聚集和LTD(4)诱导的收缩的有效抑制活性,IC(50)值分别为340 nm和0.40 nm。口服18天还抑制了LTD(4)诱导的豚鼠皮肤渗漏加速以及U46619诱导的豚鼠气道阻力增加,ED(50)值为0.47 mg / kg和3.3 mg / kg。
查看更多